Drug
Amrecibart clinical trials
Also written REGN9933.
Keep track of what changes. Save the amrecibart studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Cenvacibart (6) · REGN9533 (1)
Studies
Open first, then newest update. How each study uses amrecibart is read from its arms, and is right about nine times in ten.
Testing it · 8
- Safety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationRecruitingPhase 2Regeneron PharmaceuticalsNCT07175428Written as REGN9933
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is UnsuitableRecruitingPhase 3Regeneron PharmaceuticalsNCT07430956Written as REGN9933
- Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on HemodialysisRecruitingPhase 1Regeneron PharmaceuticalsNCT07759167Written as REGN9933
- Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)RecruitingPhase 3Regeneron PharmaceuticalsNCT07697599Written as REGN9933
- A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)CompletedPhase 2Regeneron PharmaceuticalsNCT06299111Written as REGN9933
- A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult ParticipantsCompletedPhase 2Regeneron PharmaceuticalsNCT05618808Written as REGN9933
- Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult ParticipantsCompletedPhase 1Regeneron PharmaceuticalsNCT06444178Written as REGN9933
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy VolunteersCompletedPhase 1Regeneron PharmaceuticalsNCT05102136Written as REGN9933
Given in every arm · 1 — amrecibart is usual care beside what is tested
Codes
What other systems call amrecibart · ClinicalTrials.gg INT018681
- UNII (FDA) ZDR9VW2WMNAMRECIBARTOne source FDA
- NCI Thesaurus C214499AmrecibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ZDR9VW2WMN | AMRECIBART | One source FDA |
| NCI Thesaurus | C214499 | Amrecibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.